Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 256 to 270 of 279 results for coronavirus

  1. International collaboration

    Pilar Pinilla-Dominguez reveals how NICE, through its international collaborations and partnerships, aims to contribute to improvements in health and care outcomes across the world, bringing learnings and benefits back to NICE, the NHS and the wider UK health and care system.

  2. NHS at 75

    Dr Sam Roberts, chief executive of NICE, celebrates the NHS on its 75th anniversary. She discusses how NICE has supported the NHS with its recent achievements. She also highlights how NICE is evolving; through driving value-based healthcare to support the NHS as it adapts to meet current challenges.

  3. New guidance aims to achieve fairer outcomes for looked-after children and young people

    Looked after children and young people should be considered ‘one of their own’ by carers, to help them to reach their full potential, new NICE draft guidelines say.

  4. NICE launches first modular update to its methods and processes

    NICE’s methods and processes now include a proportionate approach to technology appraisals, and a new way of updating recommendations on COVID-19 treatments.

  5. Innovative technology to detect abnormal heart rhythms recommended by NICE

    Zio XT is the first assessment, via the NICE digital health technologies guidance development pilot project, to be recommended for NHS use.

  6. NICE publishes single guideline for managing COVID-19

    One year on from the first national lockdown, NICE has today (23 March) published a single guideline for the management of COVID-19 in children and adults.

  7. Patients with rare blood disorders to receive new treatment option, says NICE

    In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).

  8. More people could be treated out of hospital in the NHS's new respiratory hubs and virtual wards

    Consultation launched on draft guidance for the assessment and management of acute respiratory infections in people over 16

  9. Speaking with one language: How using a common data model might speed up decision making

    The European Health Data and Evidence Network (EHDEN) project could support faster patient access to innovative medicines in areas of unmet need.

  10. Three treatments for COVID-19 recommended in final draft guidance

    Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments.

  11. NICE partners with international health technology assessment bodies

    Six health technology assessment (HTA) bodies from three continents are to collaborate on a range of topics that will benefit people accessing healthcare around the world.

  12. More people with rare genetic disorder eligible for nusinersen

    Following a review of data collected as part of the Managed Access Agreement, more people with spinal muscular atrophy (SMA) are to benefit from nusinersen.

  13. Public consultation on updates to health technology evaluations manual

    A public consultation marking the first update to NICE's health technology evaluations manual is now open.

  14. Evidence Evusheld is effective in protecting vulnerable adults against variants lacking, as NICE announces new rapid update process for COVID-19 medicines

    NICE issues draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 in some adults.

  15. Starting with the end in mind - the Innovative Licensing and Access Pathway

    The Innovative Licensing and Access Pathway (ILAP) will smooth the process by which innovative new medicines are developed, speeding their progression from clinical trial through to the NHS, bringing significant benefits to patients.